News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Keryx Biopharmaceuticals (KERX) Announces Live Webcast of Upcoming Analyst Day


6/19/2012 11:51:48 AM

NEW YORK, June 19, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that its upcoming Analyst Day will be webcast live on Thursday, June 21, 2012 at 4:30 pm ET. Scheduled speakers include:

Julia Lewis, M.D., will provide her perspective on the Zerenex (ferric citrate) Phase 3 clinical program and the potential Zerenex product profile.
-- Professor of Medicine, Division of Nephrology, Vanderbilt University School of Medicine.

Geoffrey Block, M.D., will discuss the potential for Zerenex in pre-dialysis.
-- Director of Research, Denver Nephrology and Associate Clinical Professor in Medicine, University of Colorado Health Sciences Center.

David Goldfarb, M.D., will discuss the potential importance of citrate.
-- Chief, Nephrology Division, NY Campus of NY Harbor Health Care Veterans Affairs System and Professor of Medicine & Physiology, NYU School of Medicine.

To access the live audio webcast, please visit the Company's Investor Relations section of their website (http://investors.keryx.com). An archived version of the webcast will become available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City.

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com

SOURCE Keryx Biopharmaceuticals, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES